


La Renon

DYDROEASE-30 SR

Dydrogesterone 30 mg (as sustained release tablets)

A Dose Towards

Easy Journey




DYDROEASE-30 SR

Dydrogesterone 30 mg (as sustained release tablets)

- » **AIM:** To compare the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone (MVP) for luteal support in vitro fertilization
- » **STUDY DESIGN:** Randomized controlled trial
- » **Total Subjects:** 1031
- » **Group A:** Oral Dydrogesterone 30 mg/day (n = 520)
- » **Group B:** Micronized vaginal progesterone 600 mg/day (MVP) (n = 511)

Result:



- ✓ Non-inferiority of oral dydrogesterone was demonstrated, with pregnancy rates at 12 weeks of gestation of 37.6% and 33.1% in the oral dydrogesterone and MVP treatment groups, respectively.
- ✓ Live birth rates of 34.6% (172 mothers with 213 newborns) and 29.8% (142 mothers with 158 newborns) were obtained in the dydrogesterone and MVP groups, respectively (%).

Conclusion:

Oral dydrogesterone may replace MVP as the standard of care for luteal phase support in IVF, owing to the oral route being more patient-friendly than intravaginal administration, as well as it being a well tolerated and efficacious treatment.

A Dose Towards *Easy Journey*



- » **AIM:** To Compare the efficacy of Oral Dydrogesterone Versus Vaginal Progesterone in Successful Pregnancy Outcome for Patients with Recurrent Pregnancy Loss
- » **Study Design:** Randomized controlled trial
- » **Total Subjects:** 200 subjects
- » **Group A:** Vaginal progesterone 600 mg/day (n=100)
- » **Group B:** Oral dydrogesterone 30 mg/day (n=100)

Result:

- The time required for complete cessation of bleeding was significantly lesser among patients who received oral dydrogesterone compared to those who received intravaginal progesterone.
- Numerically higher number of patients receiving oral dydrogesterone had a successful continuation of pregnancy up to 24 weeks of gestation, as well as till full term compared to progesterone group.
- The time required for complete stoppage of bleeding was significantly lower after receiving the oral dydrogesterone compared to intravaginal progesterone.

Conclusion:

Oral dydrogesterone is preferred over vaginal progesterone in patients presenting with vaginal bleeding during early pregnancy and a history of recurrent early pregnancy loss.



DYDROEASE-30 SR

A Dose Towards
Easy Journey



Dydrogesterone 30 mg (as sustained release tablets)


Description:

- » Each film coated sustained release tablet contains Dydrogesterone 30 mg.

Indication:

- » For Progesterone Deficiencies.
- » Endometriosis

Dydroease Benefits:



Dosage:

- » As directed by the physician.

Also available

Dydroease 10 mg

Dydrogesterone 10 mg tablets



La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,

S.G. Highway, Ahmedabad-380015, Gujarat, India.

Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998

E-mail: info@larenon.com | Web: www.larenon.com

I am: _____
Call me on: _____
Mail me at: _____

©2024 All rights reserved, La Renon Healthcare Private Limited